Robert W. Baird Raises Medpace (NASDAQ:MEDP) Price Target to $624.00

Medpace (NASDAQ:MEDP) had its price objective upped by analysts at Robert W. Baird from $547.00 to $624.00 in a research note issued to investors on Friday, MarketBeat.com reports. The firm currently has a “neutral” rating on the stock. Robert W. Baird’s target price would suggest a potential upside of 3.76% from the company’s previous close.

MEDP has been the topic of a number of other research reports. Leerink Partners set a $620.00 price objective on Medpace in a report on Thursday. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $535.00 price target on shares of Medpace in a research note on Thursday. Weiss Ratings reiterated a “hold (c+)” rating on shares of Medpace in a research report on Thursday, July 2nd. Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and raised their target price for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Finally, BMO Capital Markets boosted their target price on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research report on Friday. Two research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $560.92.

Medpace Stock Performance

MEDP stock opened at $601.38 on Friday. Medpace has a one year low of $373.00 and a one year high of $677.90. The stock has a market capitalization of $17.18 billion, a PE ratio of 35.25, a price-to-earnings-growth ratio of 2.93 and a beta of 1.15. The company has a fifty day moving average of $492.09 and a 200-day moving average of $494.49.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities analysts forecast that Medpace will post 17.59 earnings per share for the current fiscal year.

Insider Transactions at Medpace

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the sale, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC boosted its position in shares of Medpace by 65.1% in the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after buying an additional 404,226 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in Medpace by 205.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock valued at $161,523,000 after acquiring an additional 211,411 shares in the last quarter. Franklin Resources Inc. increased its holdings in Medpace by 158.6% during the 4th quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock valued at $168,198,000 after acquiring an additional 183,645 shares in the last quarter. Norges Bank acquired a new position in Medpace during the fourth quarter worth about $102,156,000. Finally, Goldman Sachs Group Inc. raised its position in Medpace by 92.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company’s stock worth $194,920,000 after acquiring an additional 166,654 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace News Roundup

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace reported stronger-than-expected Q2 results, with EPS of $4.25 topping estimates and revenue of $707.3 million exceeding forecasts, reinforcing momentum in the business. MarketWatch article
• Positive Sentiment: The company raised FY 2026 guidance to EPS of $17.25-$17.95 and revenue of about $2.8 billion-$2.9 billion, signaling confidence in continued growth and backlog conversion. Benzinga article
• Positive Sentiment: Bookings and backlog trends improved, with commentary highlighting a rebound in the net book-to-bill ratio and better revenue visibility, which supports investor optimism about future quarters. Seeking Alpha article
• Neutral Sentiment: Truist raised its price target to $609 from $462 but kept a hold rating, while Robert W. Baird lifted its target to $624 and maintained a neutral stance, suggesting analysts see upside but are not turning fully bullish. Benzinga article
• Neutral Sentiment: The stock’s move to a 52-week high reflects strong recent performance, but one Zacks note questioned whether the rally can continue, indicating the market may now be weighing valuation against the improved fundamentals. Zacks article

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.